SCHEMBL3002902

SCHEMBL3002902

COc1ccc(Cl)cc1S(=O)(=O)C1CCN(c2nc(Cc3ccc(Cl)cc3Cl)cs2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
HTT P42858 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAPK1 P28482 1/20 0.38
MAPT P10636 3/20 0.38
LMNA P02545 2/20 0.38
TSHR P16473 1/20 0.38
CPT1A P50416 6/20 0.37
CPT1B Q92523 5/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
FPR2 P25090 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017810 0.95 ALDH1A1 (0.40) TP53KDM4EALDH1A1POLBHPGD
SCHEMBL3007295 0.94 GAA (0.38) TP53KDM4EALDH1A1POLBHPGD
SCHEMBL3011425 0.91 MAPT (0.39) TP53KDM4EALDH1A1POLBHPGD
SCHEMBL3018934 0.90 DRD2 (0.40) TP53KDM4EALDH1A1POLBHPGD
SCHEMBL3006331 0.90 TP53 (0.40) TP53KDM4EALDH1A1POLBHPGD
SCHEMBL3018474 0.90 MAPT (0.40) TP53KDM4EALDH1A1POLBHPGD
SCHEMBL3015201 0.90 MAPT (0.37) TP53ALDH1A1HPGDRAB9AMAPT
SCHEMBL3013020 0.90 EPHX2 (0.39) TP53KDM4EPOLBRAB9AMAPK1
SCHEMBL3002108 0.90 ALDH1A1 (0.39) TP53KDM4EALDH1A1POLBHPGD
SCHEMBL3000548 0.89 GAA (0.38) KDM4EALDH1A1POLBRAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TP53 2880/4885KDM4E 4398/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.